Reason for the recall is a false increase of estradiol levels in patients treated with Fulvestrant Faslodex) and tested with the ARCHITECT Estradiol assay, list number (LN) 7K72. Nature of defectiveness is the interaction of Fulvestrant with the ARCHITECT Estradiol assay, leading to falsely elevated estradiol results in patients treated with Fulvestrant.